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A B S T R A C T
A 64-year-old male presented with neurofibromatosis 1 and Cushing’s syndrome. Clinically he was over weight, depressed with 
extensive skin bruising and hypertension. His 24 hours urinary metanephrines, urinary 5HIAA, gut peptides and chromgranin levels 
were normal. His renal function and renal MRI scan was also normal. His cortisol failed to suppress on overnight dexamethsone 
suppression test. His low dose dexamethasone suppression with CRH stimulation showed failure of suppression of cortisol to < 
50 nmol/L and ACTH was measurable at 10 ng/L on day 3. There was no response of ACTH or cortisol to CRH stimulation. His ACTH 
precursors were high at 126 pmol/L consistent with defective pro-opiomelanocortin (POMC) processing suggesting an ectopic source 
of ACTH production. The MRI scan of his pituitary and CT scan of the adrenal glands was normal. His octreotide scan was negative. The 
source of his ectopic ACTH was most likely a large retroperitoneal plexiform neurofibroma seen on CT abdomen that had undergone 
malignant peripheral nerve sheath tumour transformation on histology. He was a poor surgical risk for tumour debulking procedure. 
In view of the available literature and role of c-kit signalling in neurofibromatosis, he was treated with Imitinib. Four months after the 
treatment his Cushings had resolved on biochemical testing. After a year his plexiform neurofibroma has not increased in size. To our 
knowledge, this is the first case of NF1 associated with clinical and biochemical features of Cushing’s secondary to ectopic ACTH due to 
MPNST in a plexiform neurofibroma and its resolution on treatment with imatinib.
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Implication for health policy/practice/research/medical education:
Neurofibromatosis can be associated with endocrine tuomours but to our knowledge this is the first case to be associated with Ec-
topic ACTH Cushings. As this patient was a poor surgical risk for further debulking of the plexifrom neurofibroma, he was treated 
with a novel medical therapy imtinib that inhibits c-kit signalling. He responded to the treatment.
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1. Introduction
Neurofibromas are the hallmark lesions of neurofibro-
matosis 1(NF1) and are benign nerve sheath tumours. The 
estimated incidence of NF1 is 1 in 3000. Approximately 
half of affected individuals represent first case as a result 
of a new genetic mutation (1). The NF1 gene is located on 
chromosome 17, encodes a protein named neurofibro-
min that works to control cellular proliferation through 
complex interactions with ras oncogenes (2). Patients 
with NF1 have lesions that are predominantly neuroecto-
dermal or mesenchymal in origin.
Neurofibromas are categorized as localized, plexiform, 
or diffuse. Localized and plexiform neurofibromas of the 
paraspinal and sacral region are the most common ab-
dominal neoplasm in NF1 (3).
Plexiform neurofibromas are variants of neurofibro-
mas that involve a plexus of nerves or multiple fascicles 
within a medium- to large-sized nerve. They develop in 
about 40% of people with neurofibromatosis and occur 
exclusively in patients with NF1. The involved nerves re-
tain their original configuration and anatomy but are 
altered into complex, tortuous masses. Plexiform neu-
rofibromas are congenital lesions and tend to be larger, 
and more diffuse (4). These can transform to malignant 
peripheral nerve sheath tumour (MPNST). The paraspinal 
region of the abdomen, extremities, and head and neck 
region are the most common locations for MPNST (5). 
Tumours that arise in central locations such as the para-
spinal region of the retroperitoneum are associated with 
lower 5-year survival rates, higher recurrence rates, and 
higher frequency of metastasis compared with tumours 
in other areas (6, 7).
Hypertension in NF1 can be seen at any age. Many adults 
with NF1 have usual essential form of hypertension. How-
ever, any person with NF1 and high blood pressure should 
be evaluated for two causes of hypertension mainly pheo-
chromocytoma and vascular stenosis. Pheochromocyto-
ma is more common in patients with NF1 compared with 
the general population, occurring in 0.1%–5.7% of patients 
with NF1 and in 20%–50% of NF1 patients with hyperten-
sion (8).
NF1 with optic pathway tumours (OPT) has been asso-
ciated with of endocrine disorders such as growth hor-
mone excess and precocious puberty (9).
NF1 can also be associated with a variety of endocrine 
tumours including somatostainoma, gastrointestinal 
stromal tumour (GIST) (10) and primary hyperparathy-
roidism (11).
We report a case of 64-year-old man who presented with 
clinical and biochemical features of Cushings due to ec-
topic ACTH syndrome in the setting of NF-1. The source 
of his ectopic ACTH secretion was most likely from the 
plexiform neurofibroma with MPNST. His treatment with 
Imatinib a tyrosine kinase inhibitor led to resolution of 
his Cushing's syndrome.
2. Case Report
A 64 years old male with NF1 had multiple hospital ad-
missions with abdominal and back pain between 2003 
and 2004. He had lost significant amount of weight. As 
a part of work up he had MRI scan of the abdomen and 
pelvis. His scans showed a large pre-sacral mass in left 
retroperitoneal region with possible infiltrative charac-
teristics. This mass extended up to left lesser trochanter 
and also had some calcification in it (Figure 1). 
Figure 1. Mass Extending to Left Lesser Trochanter With Some Calcifica-
tion
A diagnosis of plexiform neurofibroma was made. In 
2008 he had acute abdominal pain following trauma. 
There was possibility of a haematoma in the retroperi-
toneal mass on imaging. He had surgery with drainage 
of haematoma and debulking of retroperitoneal mass. 
He bled heavily during the surgery and required blood 
transfusion. The mass removed surgically showed dif-
fuse involvement of nerve segment and its branches 
with tortuous expansion. Histology revealed spindle 
cell tumour infiltrating adjacent fat and entrapping 
nerve bundles (Figures 2 and 3).
Figure 2. Spindle Cell Tumour Infiltrating Adjacent Fat and Entrapping 
Nerve Bundles. Tumour Cells Were Positive For s100 Protein Immunos-
tains
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Figure 3. Immunochemical Staining of The Tumour Did Not Show Posi-
tive Staining for Acth
Tumour cells were positive for S100 protein immunos-
tains. These features were consistent with malignant 
peripheral nerve sheath tumours. He was reviewed in 
genetic endocrine clinic. He appeared depressed and 
was overweight with a BMI of 29kg/m2. He had exten-
sive bruising of skin on his arms and legs and his blood 
pressure was 160/100mmHg. He had no abdominal stri-
ae or proximal muscle weakness. His 24 hours urinary 
metanephrines and 5 HIAA were normal. His serum po-
tassium, renal function and renal MRI scan was normal. 
He had a 2 cm enhancing mass in the wall of the second 
part of the duodenum representing neurofibroma. His 
gut peptides, chromgranin A and B were normal. His oc-
treotide scan was negative.
He had overnight dexamethasone suppression test and 
his cortisol failed to suppress. He had low dose dexameth-
asone suppression test (LDDST) combined with CRH stim-
ulation. At baselne he had measurable ACTH of 29ng/L 
with cortsiol of 689nmol/L. His cortisol was 427nmol/L on 
day three of low dose dexamethasone and his ACTH was 
10ng/L consistent with ACTH dependent Cushing’s. After 
100mcg of CRH there was no increase in cortisol or ACTH 
level. His ACTH precursors were high at 126 pmol/L (Table 
1). A CT scan of his adrenals and MRI scan of the pituitary 
gland was normal. Patient did not have inferior petrosal 
sinus sampling in view of normal pituitary MRI scan, 
multiple neurofibromas and previous history of bleed-
ing on surgery.
A diagnosis of Cushing’s syndrome due to ectopic ACTH 
was made. The source of ectopic ACTH was most likely 
his large retroperitoneal plexiform neurofibroma with 
MPNST. This patient was a poor surgical risk for further 
debulking of the plexifrom neurofibroma. He was treat-
ed with Imatinib mesylate at a daily dose of 75 mg/kg for 
4 weeks.
He had repeat LDDST with CRH stimulation 4 months 
after the treatment. His cortisol suppressed to 27 nmol/L 
and ACTH was < 5ng/L on day 3. There was no response of 
cortisol or ACTH to CRH (Table 2). His MRI scan of the ab-
domen one year after treatment with imitinib showed no 
increase in the size of plexiform neurofibroma but there 
is a definite decrease in the density of plexiform mass. 
Immunochemical staining of the tumour did not show 
positive staining for ACTH.
Table 1. Low Dose Dexamethasone Suppression Test Combined 
with CRH Stimulation
Day Time Cortisol, nmol/L ACTH, ng/L
1 0 689 29
3 0 427 10
 15 401 13
 30 403 15
No suppression of cosrtisol on day 3 after low dose dexamethasone and 
no increase in cortisol or ACTH after CRH stimulation
ACTH:35ng/L
ACTH precursors:126pmol/L
Table 2. Low Dose Dexamethasone SuppressionTest Combined 
With CRH Stimulation After Imitinib Therapy
Day Time Cortisol a, nmol/L ACTH, ng/L
1 0 691 67
3 0 23 < 5
 15 24 < 5
 30 29 < 5
a Suppression of cosrtisol on day 3 after low dose dexamethasone 
with suppressed ACTH and no increase in cortisol or ACTH after CRH 
stimulation indicates normal response
3. Discussion
Neurofibromatosis evolves from mutations in the NF1 
tumor suppressor gene. It leads to recruitment of mast 
cells into neurons via c-kit signalling. The mast cells then 
initiate matrix formation and angiogenesis required for 
neurofibroma development (12). The natural history 
of plexiform neurofibromas has not been clearly eluci-
dated but they do have potential for malignant trans-
formation to malignant peripheral nerve sheath tumor 
(MPNST). MPNSTs are not uncommon in adolescents 
and adults with NF1. The lifetime risk of developing an 
MPNST for a person with NF1 is 4%–5% (13). MPNST is an 
aggressive malignancy and can be fatal due to organ 
invasion or malignant transformation. These tumors 
do not respond to chemotherapy and can be difficult if 
not impossible to remove surgically. MPNSTs in patients 
with NF1 carry a poorer prognosis than in patients with-
out this condition and tumor volume is an independent 
prognostic indicator (14).
The Ectopic ACTH syndrome (EAS) occurs in around 
5–10% of all cases of ACTH-dependent hypercortisolism 
(15).
Ectopic ACTH- and CRH-secreting tumors arise from 
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nonpituitary neoplasms, and may be clinically overt 
or occult. Ectopic ACTH secretion Cushing's syndrome 
is associated with significant morbidity and mortality. 
Management of this Cushing’s requires control of the 
hypercortisolaemia as well as identification and treat-
ment of the underlying source adrenocorticotrophin. 
ACTH is derived by cleavage from the precursor, pro-
opiomelanocortin (POMC). In human pituitary POMC 
is enzymatically processed to pro-ACTH, which is then 
cleaved to give ACTH (16). Ectopic 'ACTH' is character-
ized by aberrant processing of POMC. POMC express-
ing cells can potentially secrete number of ACTH re-
lated peptides depending on the degree of processing 
by the tissue or tumor. The precursors of ACTH (POMC 
and proACTH) in the circulation of normal subjects are 
in the range of 5-40 pmol/L (17). Pituitary tumors have 
low levels of ACTH precursors (below 100 pmol/L) and 
the mean ratio of ACTH precursors to ACTH is 5:1. In ec-
topic Cushing's Syndrome,the extra pituitary tumour 
cells are unable to process POMC efficiently. Therefore 
there is an increased level of ACTH precursors in the cir-
culation in patients with the ectopic ACTH Syndrome. 
The diagnostic accuracy of the measurement of ACTH 
precursors has been compared with the current "gold 
standard" test of inferior petrosal sinus sampling (IPSS). 
All patients with ACTH precursors below a diagnostic 
cut-off of 100 pmol/L were subsequently shown to have 
pituitary tumors, whereas levels of >100 pmol/L were 
seen in patients with ectopic ACTH producing tumors. 
Therefore measurement of ACTH precursors offers a 
simple non-invasive diagnostic test for the differential 
diagnosis of Cushing's syndrome and compares favour-
ably with IPSS (18).
Patients with NF1 are at an approximately 2–4 fold high-
er risk of developing tumors than the general population 
with a risk of malignancy estimated at between 5 and 
15 percent (19, 20). The gastrointestinal tract may be in-
volved in NF-1 and includes mucosal and myenteric nerve 
hyperplasia, gastrointestinal stromal tumors (GIST), car-
cinoids, pheochromocytomas, paragangliomas, as well 
as pancreatic neuroendocrine tumors (21).
Neurofibromin is a tumor suppressor gene and muta-
tions in NF-1 cause increased activation of ras and in-
creased signaling via downstream pathways, including 
the mitogen-activated protein kinase (MAPK) pathway 
and the mammalian target of rapamycin (mTOR) path-
way. mTOR is a member of the phosphoinositide-3-ki-
nase-related family, and serves as a critical mediator of 
cell growth and proliferation, responsible for stimulat-
ing cell growth and controlling cellular energy levels. 
Pathogenic mutations of neurofibromin lead to constitu-
tive activation of downstream pathways and subsequent 
tumor development (22).
Imatinib inhibits c-kit signalling. It is an approved treat-
ment for chronic myeloid leukemia and certain stomach 
and digestive system tumours (23, 24). Imatinib mesylate 
(Glivec) is known to inhibit Schwann cell viability and to 
reduce the size of human Plexiform neurofibroma in a 
xenograft model.The discovery that c-kit plays a central 
role in neurofibromatosis evolution led the investigators 
to use Imatinib (25).
Initial compassionate use of the drug in a three-year-
old girl with the NF1 resulted in about 70% shrinkage of 
a plexiform neurofibroma that was causing life-threat-
ening airway compression (26). There is an ongoing 
Pilot Study to determine the efficacy of imitanib in NF1 
patients with plexiform neurofibromas using new re-
sponse assessment modalities with the secondary goals 
of assessing imitanib toxicity, and characterizing mark-
ers of response. Imtinib is being used in different doses 
starting from 400mg to 800mg a day. The treatment will 
be continued for 6 to 24 if the patient is deriving a clinical 
benefit (27). Our case of NF1 presented with Cushings due 
to ectopic ACTH. The source of ectopic ACTH was thought 
to be his large retroperitoneal plexiform neurofibroma 
with MPNST. The ACTH staining for the tumour removed 
surgical was negative.
As this patient was a poor surgical risk for further de-
bulking of the plexifrom neurofibroma, we treated him 
with Imatinib mesylate at a daily dose of 75 mg/kg for 
4 weeks. He had no side effects from the drug. His re-
peat tests 4 months after the treatment suggest that his 
Cushings has resolved. His plexiform neurofibroma has 
remained stable. His mass probably would shrink if we 
used imatninb for longer period of time. To our knowl-
edge this is the first case report of Cushing’s due to an 
Ectopic ACTH associated with NF1 and its treatment with 
imatinib in an adult.
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